Trial · NCT02050360
"As Required" Oral Sildenafil in Raynaud's Phenomenon
NCT02050360, Phase 2, Phase 3, Completed, University Hospital, Grenoble
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. "As Required" Oral Sildenafil in Raynaud's Phenomenon. Trials, record NCT02050360. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02050360
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- "As Required" Oral Sildenafil in Raynaud's Phenomenon
- NCT number
- NCT02050360
- Status
- Completed
- Phases
- Phase 2, Phase 3
- Enrollment
- 41 participants, actual
- Lead sponsor
- University Hospital, Grenoble
- Conditions
- Raynaud's Phenomenon
- Interventions
- Sildenafil 40 mg, Sildenafil 80 mg, Placebo
- First posted
- 2014-01-30
- Last updated
- 2016-01-18
- Other registries' IDs
- eudract:2013-000014-38
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Mean change in the Raynaud's Condition Score (RCS) during treatment, as compared to placebo. | 7 days | RCS is self-reported every day and averaged over 7-day periods |
| Secondary | Frequency of RP: number of RP attacks during treatment, as compared to placebo. | 7 days | An attack is defined as an episode of pallor or cyanosis (with or without pain,tingling or numbness). The number of attacks is self-reported every day and averaged over 7-day periods |
| Secondary | Patients' preference: comparison between the number of patients favoring a treatment to another. | Every 3 weeks of treatment (week 3, 6 and 9) | |
| Secondary | Pain associated with RP: Mean change in the Raynaud's pain score during treatment, as compared to placebo. | 7 days | Pain associated with each attack is self-reported on a 10-point scale, and averaged over 7-day periods |
| Secondary | Frequency and severity of adverse drug events during treatment, as compared to placebo | 7 days | |
| Secondary | Microvascular reactivity: index of skin perfusion in response to local/regional cooling after a single dose of sildenafil, as compared to placebo (laboratory experiments) | Week 1, 2 and 3 |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02050360
GET https://conductscience.org/api/trials/v1/NCT02050360/registered